New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia

Shizuya Yamashita, chairman of JAS's guidelines drafting committee The new guidelines being drafted by the Japan Atherosclerosis Society, due out in 2017, are expected to recommend the use of PCSK9 inhibitors for the primary prevention of coronary artery disease (CAD)...read more